Seasonal Influenza Vaccine

Healthcare · §657

Catching the flu raises your odds of a heart attack about sixfold in the week after — an old plaque, calmly managed for years, tears open under the inflammatory hit. The ten-minute pharmacy shot, once a year, takes that window down. It also subtracts, in the years it lands, the week of fever and the three weeks of post-viral fog where even your hair hurts. The win is mostly invisible — a heart attack you don't have, a week your calendar doesn't lose — which is exactly why it gets skipped.

Do · Yearly Evidence Moderate Chapter Healthcare

In anyone with established heart disease, the shot cuts major cardiac events roughly a third in the year that follows — the same league as a high-intensity statin, for $30 and a needle. For everyone else, it cuts the odds of a typical-flu week — high fever, body-ache where even your hair hurts, three-week tail of fog — by about half. Free at most pharmacies, ten minutes, once a year. The catch: it's a chore, the events it prevented are invisible, and most people quietly skip the year they shouldn't have.

Your immune system runs on memory. The vaccine shows it a piece of this winter's flu virus — the spike protein that lets the virus latch onto cells in your nose and throat — and gives it three or four weeks to learn the shape. When the real virus shows up in February, antibodies that recognise that shape are already waiting at the door, and the infection is shorter, milder, or stopped at the threshold. That's the whole story.

Two details matter for the choice you'll actually make. First: the flu virus rewrites itself a little every year. The strain in your 2024 shot isn't the one circulating in 2026, which is why this is one of the few vaccines you have to re-take annually. Second: the immune response weakens with age. By 65, a standard dose generates strong antibody response in only about half of recipients (versus four out of five at 30), which is why the formulations marked high-dose, adjuvanted, or recombinant exist — they're built to compensate, and a 32,000-person trial in adults over 65 found high-dose cut symptomatic flu about a quarter further than the regular shot, plus measurable drops in serious pneumonia and hospitalisation.

What you're actually trading against

The flu people remember is the one that sent them to bed for a week. Fever 39+, body-ache where rolling over hurts, a cough that wakes the person sleeping next to you. You don't make decisions in that week; you wait it out. Then there's a tail — three weeks where stairs feel like a hill, where the meeting you used to run goes differently because you can't quite hold the thread. For working adults under 65 this is the central thing the vaccine subtracts from your odds: not every year, but the year it would have happened.

The piece most readers don't know sits in the cardiovascular tail. In the seven days after a confirmed flu infection, your odds of an acute heart attack go up roughly sixfold. The data is unusually clean — Ontario researchers cross-checked confirmed-flu cases against hospital admissions in the same patients in the years before and after, so each person is their own control. Strokes and heart-failure flares show the same pattern. The mechanism is straight inflammation: the fever-and-cytokine response that's clearing the virus also destabilises whatever atherosclerotic plaque you had quietly carrying around. For anyone with a coronary stent, prior heart attack, diabetes, or family history of early heart disease, that's the load-bearing reason to get the shot.

For the elderly and those with chronic lung or heart disease, the flu itself remains a leading cause of winter death — global modelling puts seasonal influenza at 290,000 to 650,000 respiratory deaths a year, with mortality climbing sharply past 75 Iuliano et al. 2018. The under-65 healthy reader is mostly buying themselves a calmer winter; the over-65 or cardiovascular-risk reader is buying something bigger.

How to actually do it

The whole protocol is: get the shot once a year, ideally between mid-September and the end of October, at a pharmacy. You don't need an appointment in most countries. The immune response peaks two to four weeks after the injection and tapers across the six months that follow, which is why the calendar matters — get it too early (August), and you've waned by February's peak; get it too late (January), and you may not have built up before exposure.

Timing. Aim for late September through end of October in the northern hemisphere. December is still worth doing; the season often runs through March ACIP 2024.
If you're under 65 and otherwise healthy. Any standard-dose product is fine. The recombinant version (Flublok) and cell-grown version (Flucelvax) are reasonable choices if you can pick — slightly better against H3N2 in mismatched years — but the marginal difference for a healthy adult is small.
If you're 65 or older. Specifically ask for one of three: high-dose (Fluzone HD), adjuvanted (Fluad), or recombinant (Flublok). The official guidance prefers any of these over the standard shot at this age ACIP 2024.
If you have heart disease, a prior heart attack, diabetes, or chronic lung disease. This is the year you don't skip. Talk to your cardiologist or primary about which formulation; under most secondary-prevention guidelines, an annual flu shot is now a Class I recommendation.
If you're pregnant. Inactivated shot, any trimester. The antibodies cross the placenta and protect the baby for the first six months.

You'll need 10 to 20 minutes including the post-shot observation period. Expect a sore arm for 24-48 hours, occasionally a mild low-grade fever or fatigue the next day. Take the shot in your non-dominant arm if you can — you'll sleep on the other side more easily.

When to be careful

Egg allergy used to be a special-handling case; it isn't anymore. The 2024 guidance dropped the requirement for special precautions even with egg-grown vaccines — the egg-protein amount is too small to matter clinically ACIP 2024. If you have a moderate cold or fever the day of the appointment, push it a week. A genuine acute illness blunts the immune response and there's no upside to vaccinating while sick.

What people get wrong

"The shot gives you the flu." It can't. Every injectable version contains either inactivated virus or just the spike protein — no live, replicating virus, no ability to infect a cell. The sore arm and 24-hour low-grade fever some people get the day after are the immune system doing its job, not a mild flu. The nasal spray contains live attenuated virus but is engineered to grow only in the cool tissue of the nose; it doesn't cause systemic illness.

"I got the shot and still got sick." Usually true and usually not the flu. The same months that flu circulates — November through March — also carry RSV, common-cold coronaviruses, rhinovirus, and several others, all of which produce a fever-cough-aches week that feels like flu. A throat swab can tell them apart; without one, most "flu" by self-report is not flu. The few that are flu are usually shorter and milder for the vaccinated reader.

"I'm young and healthy, I don't need it." The individual benefit is smaller than for an elderly reader — but the studies in healthy adults still show roughly halving of confirmed-flu odds, and the community-protection argument is the other half of the case. Your shot makes you less likely to be the link in the chain that ends at the infant niece or grandmother on chemo who can't mount a vaccine response of their own.

"Last year's was good, so I'm covered." No. The virus shifts a little every year, and your antibody levels measurably wane across six months. The vaccine is reformulated each February for the coming winter; using it annually is the design.

Why it sometimes underperforms

Two reasons. First: strain mismatch. Public health authorities pick the strains in February, eight months before the season starts, and the H3N2 component drifts the fastest. In bad-match seasons like 2014-15, real-world effectiveness against confirmed flu dropped to roughly 19%. That's the floor, not the average — in better-matched years the pooled estimate is 50-60%.

Second: the egg problem. Most flu vaccines are grown in chicken eggs, a process that subtly mutates the virus's spike protein in ways that drift it away from the wild type. The H3N2 strain is most sensitive to this. The recombinant (Flublok) and cell-grown (Flucelvax) products skip eggs entirely and tend to perform better in H3N2-heavy years — worth asking for if you're choosing.

The reader-level takeaway: in a bad-match season, a vaccinated person who catches flu is still meaningfully less likely to be hospitalised than an unvaccinated one. The vaccine's protection against severe disease holds up better than its protection against any infection at all — even when antibody response doesn't quite match the spike, it usually still tempers severity.

Where the calculus shifts

Most adults are getting a real but modest individual benefit and a real community benefit. A few groups are getting something much larger, and the choice tips harder for them.

Adults 60+. The case is about as strong as adult preventive medicine gets. Your baseline risk of being hospitalised or killed by flu is higher; your standard-shot antibody response is weaker; and the enhanced products (high-dose, adjuvanted, recombinant) close most of that gap. The 32,000-person high-dose trial showed roughly a quarter fewer confirmed-flu cases plus measurable reductions in pneumonia and hospitalisation. Ask for one of the three enhanced products by name — pharmacies usually have them, but the default they hand you might not be one.

Anyone with cardiovascular disease. This is the group where the vaccine starts to look like a cardiac drug. The IAMI trial randomised heart-attack patients within 72 hours of their stent placement to flu vaccine or placebo and found 41% lower all-cause mortality at one year in the vaccinated arm Frobert et al. 2021. Across all the trials in coronary-disease patients, the consistent finding is roughly a third fewer major cardiac events in the year that follows Behrouzi et al. 2022. European and American cardiology guidelines now treat annual flu vaccination as standard secondary prevention after a heart attack — same status as a statin.

Pregnant women. Inactivated shot at any point in pregnancy. The infection itself is unusually rough during pregnancy (more hospitalisation, more pre-term delivery), and the antibodies cross the placenta — your shot in the third trimester protects the baby for the first six months of life, the months they can't be vaccinated themselves.

Healthcare workers and live-in carers. Your personal risk reduction is the same as any healthy adult's; the larger reason to do it is the patients and family members you'd otherwise transmit to during their treatment window. Most hospital systems make this mandatory, with reason.

What you actually get back

Most of it is invisible — the events you don't notice because they didn't happen. The honest shape:

Days after. A sore arm. The occasional mild fever the next morning. The decision is made; you move on.

The winter that follows. Across the population, vaccinated adults catch confirmed flu roughly half as often as unvaccinated ones — but the typical reader doesn't catch flu in any given year, so the felt benefit is mostly probabilistic. The year it pays out, it pays out big: the week of high fever and the three-week tail of fog you don't have to live through.

A year out, for the cardiovascular-risk reader. The clearest effect in the literature. A third fewer cardiac events at twelve months in anyone with a recent heart attack or established coronary disease Behrouzi et al. 2022. The phone call your cardiologist doesn't have to make to your family. The retirement that arrives intact instead of curtailed by a winter event everyone had been calmly managing the underlying risk for.

A decade in. For the over-65 reader, repeated annual vaccination across a decade is one of the few interventions that measurably shifts winter all-cause mortality at the population level DiazGranados et al. 2014. For the healthy 30-year-old, it's the absence of roughly half the bad winters you'd otherwise have had — and the moral relief of knowing the chain that runs from you to the people who can't get the shot stops a little shorter.

Adjacent things worth knowing

The flu shot is one of several adult vaccines that move the needle yearly or once-in-life — none of them substitutes for the others, and most readers under-do all of them. The COVID-19 booster runs on the same fall calendar; the two can be given at the same appointment, opposite arms. Over 50, the shingles vaccine (Shingrix, two doses, lifelong) is the single most under-prescribed adult vaccine for its impact. Over 65, the pneumococcal vaccines (PCV20 or PCV15+PPSV23) and the RSV vaccine are the natural companions to the annual flu shot. After 50 with any risk factor, the cardiovascular case for the flu shot becomes a cardiovascular case for understanding your apoB and your blood pressure too.

If you do catch flu despite the shot, the antivirals (oseltamivir, baloxavir) shorten the course by roughly a day if started within 48 hours of symptom onset — worth knowing about, especially if you're high risk; a different decision from the prevention question.

Substance and claimed effects

The seasonal influenza vaccine is an annually-reformulated injectable (or, less commonly, intranasal) immunisation against the strains of influenza A and B virus predicted to circulate in the coming winter. Manufacturers and public health bodies — CDC/ACIP, WHO, ECDC — make a four-strain selection (two A subtypes, two B lineages) each February for the northern hemisphere; from 2024–25 the WHO recommended dropping the B/Yamagata component, making most products trivalent again ACIP 2024. The catalogue covers all licensed adult formulations: standard-dose inactivated quadrivalent / trivalent, the egg-free recombinant product (Flublok), the cell-based product (Flucelvax), the high-dose product for ≥65 (Fluzone High-Dose / Efluelvax HD), the adjuvanted product for ≥65 (Fluad), and the live attenuated nasal spray (FluMist, ages 2–49). Claimed effects for which scoring is required: reduced incidence and severity of symptomatic influenza, reduced hospitalisation and mortality (especially in older and chronically ill adults), reduced post-infection cardiovascular events (acute MI, stroke, heart failure decompensation), partial reduction in onward transmission, and the constellation of short-term reactogenicity (sore arm, low-grade fever, fatigue 24–48h). Out of scope: pandemic and pre-pandemic H5/H7 vaccines, universal-influenza-vaccine candidates in trials, paediatric primary series in <9-year-olds.

Evidence by addressing question

mechanism

Influenza vaccine works by training the adaptive immune system against the surface haemagglutinin (HA) and, to a lesser extent, neuraminidase (NA) glycoproteins of the predicted strains. Inactivated and recombinant products generate strain-matched anti-HA antibody titres (the haemagglutination-inhibition / HAI titre is the canonical correlate of protection — a post-vaccination titre ≥1:40 is the regulatory threshold associated with ~50% reduction in clinical disease). The live attenuated nasal spray induces both mucosal IgA and systemic responses. Antibody response declines with age: in the >65 cohort, standard-dose vaccine generates seroconversion in roughly half of recipients vs ~80% in healthy adults, which is the rationale for the two enhanced products. High-dose (Fluzone HD) contains 60 µg of HA per strain, four times the standard 15 µg, eliciting markedly higher post-vaccination HAI geometric mean titres DiazGranados et al. 2014. Adjuvanted (Fluad) uses MF59, an oil-in-water squalene emulsion, to amplify the response to standard-dose antigen. Recombinant (Flublok) bypasses the egg-adaptation problem — eggs select for mutations that drift the seed strain away from the circulating wild type, especially for H3N2 — by producing HA in a baculovirus expression system; this matters because H3N2 effectiveness has been disproportionately poor when egg-adaptation introduces antigenic changes Dunkle et al. 2017.

evidence

For healthy adults under 65, the Cochrane systematic review of 52 RCTs (over 80,000 participants) concluded that influenza vaccine reduces symptomatic, laboratory-confirmed influenza from ~2.3% to ~0.9% (a risk reduction from roughly 23 to 9 per 1,000) — a number-needed-to-vaccinate of around 71 to prevent one case in a typical season. The effect on influenza-like illness (a broader, less specific endpoint) is much smaller in absolute terms because most ILI is not influenza Demicheli et al. 2018. For seasonal vaccine effectiveness, the long-running test-negative design meta-analysis pooled 56 studies and estimated 61% VE against H1N1pdm09, 54% against B, and only 33% against H3N2 — the H3N2 deficit is consistent across seasons and is the field's central effectiveness problem Belongia et al. 2016. The Osterholm meta-analysis (31 studies) found pooled VE of 59% in healthy adults 18–65 across seasons of reasonable strain match Osterholm et al. 2012.

For adults ≥65, the Cochrane review of trials and observational studies found low-quality evidence that vaccination reduces influenza incidence from ~6% to ~2.4% and ILI from ~6% to ~3.5%; mortality and serious complications were too heterogeneously studied to pool with confidence Demicheli et al. 2018. The landmark high-dose RCT (~32,000 community-dwelling ≥65 adults, FIM12 trial) showed 24.2% relative efficacy of high-dose over standard-dose against laboratory-confirmed influenza, plus reductions in serious pneumonia (-39.8%), cardiorespiratory events, and all-cause hospitalisation DiazGranados et al. 2014. The meta-analysis of 25 studies aggregating high-dose vs standard-dose data confirmed the effect in real-world use across seasons Lee et al. 2018. The recombinant vaccine RCT in ≥50 adults (~9,000 participants) showed 30% relative efficacy over standard-dose during an H3N2-dominant season — the same H3N2 effectiveness gap that egg adaptation drives Dunkle et al. 2017. The adjuvanted (MF59) vaccine shows comparable enhancement in older adults vs standard dose, with effectiveness sitting between standard and high-dose in head-to-head observational comparisons Tinoco et al. 2023.

For cardiovascular outcomes, the evidence is unusually strong for what reads as a non-cardiac intervention. The IAMI trial (n=2,571) randomised post-MI / high-risk stable CAD patients within 72 hours of PCI to flu vaccine vs placebo and found a 28% reduction in the composite of all-cause death, MI, or stent thrombosis at 12 months (5.3% vs 7.2%, HR 0.72) and a 41% reduction in all-cause death (HR 0.59) Frobert et al. 2021. The Udell meta-analysis pooled five trials in patients with established CAD and found a 36% reduction in major cardiovascular events (RR 0.64) Udell et al. 2013. The updated Behrouzi meta-analysis of six RCTs (~9,000 patients) confirmed a 34% reduction in MACE in patients with recent acute coronary syndrome and ~20% in mixed CV cohorts; the effect size is in the range of optimised LDL lowering Behrouzi et al. 2022. The mechanistic basis is concrete: influenza infection produces a documented acute MI signal — the self-controlled case series of 364 confirmed-influenza patients in Ontario found a 6.05-fold increase in acute MI risk in the 7 days after laboratory-confirmed influenza Kwong et al. 2018, plus parallel signals for stroke and heart failure decompensation. Pre-vaccination case-control work had already shown the same pattern: recent flu infection roughly doubles MI risk, and vaccination roughly halves it MacIntyre et al. 2013.

For transmission, the cleanest data is the Hutterite cluster RCT: vaccinating children in 49 Hutterite colonies cut laboratory-confirmed influenza in unvaccinated community members by 61% — direct evidence of herd protection at the population level Loeb et al. 2010. Observational household-transmission studies show smaller, more variable effects; the field consensus is that influenza vaccine reduces transmission modestly in adults and substantially when paediatric coverage is high, but it is not as effective an outbreak-stopper as, for instance, measles vaccine.

protocol

ACIP recommends annual vaccination for everyone ≥6 months who has no contraindication, with seasonal timing: ideally by the end of October in the northern hemisphere (immune response peaks 2–4 weeks post-injection and persists with measurable waning over 6 months) ACIP 2024. For adults ≥65, ACIP since 2022 has preferentially recommended one of three enhanced products: high-dose (Fluzone HD), adjuvanted (Fluad), or recombinant (Flublok); if none available, standard-dose is acceptable. For pregnant women, inactivated vaccine in any trimester is recommended — the live attenuated nasal spray is contraindicated. Healthy adults under 65 may use any inactivated, recombinant, or (in 2–49) live attenuated product. Egg allergy is no longer a meaningful contraindication for any product, including egg-grown vaccines (the 2024 ACIP update removed the special precaution).

contraindications

Absolute contraindication: severe (anaphylactic) prior reaction to a previous influenza vaccine or one of its components. The live attenuated nasal spray (LAIV) is contraindicated in immunocompromised patients, pregnant women, children <2, adults ≥50, those with severe asthma or aspirin therapy in children, and close contacts of severely immunocompromised patients in protected environments ACIP 2024. Guillain-Barré syndrome within 6 weeks of a prior influenza vaccine is a precaution, not a strict contraindication; the absolute risk attributable to the vaccine is roughly 1–2 cases per million doses, and is smaller than the GBS risk from natural influenza infection itself.

misconceptions

The persistent myths are (i) "the shot gives you the flu" — biologically impossible for the inactivated and recombinant products (no replication-competent virus); the post-shot 24–48h sore-arm-and-mild-fever picture is the immune response, not influenza; (ii) "healthy young adults don't need it" — the Cochrane data Demicheli et al. 2018 shows a real if modest individual benefit, and the community-protection argument is the additional case; (iii) "last year's vaccine is fine" — antigenic drift and the seasonal reformulation make annual revaccination the rule; (iv) "the vaccine doesn't work because I got the flu after getting it" — most cases of ILI are not influenza (RSV, rhinovirus, coronaviruses circulate the same months), and even for confirmed influenza VE of 40–60% means breakthrough infection is common but typically milder.

failure-modes

The dominant failure mode is strain mismatch. The H3N2 component is selected ~8 months before the season starts, giving the virus time to drift; egg-grown H3N2 also accumulates passage-adaptation mutations that drift the vaccine antigen further from the wild type. In seasons like 2014–15 (H3N2-dominant, drifted) VE against medically attended influenza dropped to ~19%. Cell-based and recombinant products bypass the egg-adaptation channel and have shown advantage in H3N2 seasons Dunkle et al. 2017. The second failure mode is timing: vaccinating in August produces measurable antibody waning by February–March, when the bulk of season often peaks; vaccinating in November–December gives stronger late-season protection but risks missing an early peak. ACIP's compromise is "by end of October" ACIP 2024. The third is repeated-vaccination interference: observational data hint that recipients vaccinated in both the current and prior season have slightly lower VE than those vaccinated in only the current season — effect sizes are small and inconsistent across seasons, and the policy implication is that you should still get vaccinated every year because the upside dominates McLean et al. 2014.

practicalities

In the United States: covered with zero copay under all ACA-compliant plans and Medicare Part B (annual flu shot included as a preventive service). Out-of-pocket cost where uninsured is typically $25–75 per dose at a pharmacy; enhanced ≥65 products around $70–90. Administration time at a pharmacy: 10–20 minutes including the post-shot observation period. Time off needed: typically none, though arm soreness for 24–48h and an occasional low-grade fever are realistic. UK NHS: free for at-risk groups and ≥65; EU coverage varies by country.

history

The first inactivated influenza vaccines were developed in the 1940s by Thomas Francis and Jonas Salk for the US military. The WHO Global Influenza Surveillance Network (now GISRS), founded in 1952, supplied the predictive strain-selection infrastructure that makes annual reformulation possible. The 1968 H3N2 Hong Kong pandemic introduced what remains the most antigenically drift-prone component of the seasonal vaccine. The high-dose product was licensed in 2009, the recombinant in 2013, and the cell-based in 2012; ACIP's preferential ≥65 recommendation came in 2022.

stakes

Global modelling estimates seasonal influenza causes 290,000–650,000 respiratory deaths annually, with mortality concentrated in adults ≥75 (51.3 per 100,000) and those with chronic respiratory or cardiovascular disease Iuliano et al. 2018. In the United States the CDC estimates seasonal averages of 9–41 million illnesses, 140,000–710,000 hospitalisations, and 12,000–52,000 deaths per year. The cardiovascular tail is the under-appreciated burden: the 6-fold acute-MI signal in the week post-infection Kwong et al. 2018 means an unknown but substantial fraction of mid-winter heart attacks are influenza-triggered. For working adults the felt stakes are the 5–7 days of incapacitation (high fever, myalgia, productive cough, profound fatigue) typical of confirmed influenza, plus post-viral fatigue of 1–3 weeks; sequelae include pneumonia (bacterial superinfection), myocarditis, otitis media, and prolonged decompensation of underlying chronic disease (asthma, COPD, CHF, diabetes).

payoff

Individually: a 40–60% relative reduction in the chance of getting symptomatic influenza in a typical season, and meaningful attenuation of severity even when breakthrough occurs (hospitalisation reduction is consistently larger than illness reduction). For ≥65, additionally: ~24% relative reduction in symptomatic cases on standard-dose, with enhanced products adding further protection DiazGranados et al. 2014; reductions in serious pneumonia, cardiorespiratory hospitalisation, and all-cause mortality. For anyone with established CAD or recent ACS: a ~28–34% reduction in major cardiovascular events at one year — an effect size comparable to high-intensity statin therapy at far lower cost and effort Frobert et al. 2021 Behrouzi et al. 2022. Collectively: reduced community transmission, lower healthcare-system strain in peak season, protection of immunocompromised contacts who cannot mount a robust vaccine response themselves.

out-of-scope

Pandemic preparedness and universal-influenza-vaccine research are separate trajectories. The COVID-19, pneumococcal (PCV15/20, PPSV23), RSV, herpes zoster (Shingrix), and Tdap vaccines are adjacent adult immunisations the catalogue should index. Antivirals (oseltamivir, baloxavir) for established influenza are a treatment question, not a prevention question.

The credibility range

The optimist case. Annual influenza vaccination is one of the most-studied preventive interventions in medicine, with the best-evidenced CV protective effect outside lipid-lowering therapy. The IAMI trial Frobert et al. 2021 alone would justify recommending it to every post-MI patient; the Udell Udell et al. 2013 and Behrouzi Behrouzi et al. 2022 meta-analyses confirm the cardiac effect with consistent point estimates across trials. The Hutterite cluster RCT Loeb et al. 2010 provides direct community-protection evidence. High-dose efficacy in the FIM12 RCT DiazGranados et al. 2014 is well within Cochrane Level 1 evidence. The intervention is essentially free, ten minutes annually, and net-positive in every cost-effectiveness analysis done in the past two decades.

The skeptic case. The Cochrane reviews Demicheli et al. 2018 Demicheli et al. 2018 emphasise that the absolute risk reduction in healthy adults is small (NNV ~71), and that ILI — the endpoint most readers care about — is only modestly affected because most ILI is not influenza. Test-negative design effectiveness against H3N2 is poor (33%) Belongia et al. 2016, and observational mortality reductions in the elderly were overstated for two decades by healthy-vaccinee bias before the high-dose RCTs corrected the picture. The CV effect, while real, has been demonstrated in selected populations (recent ACS, established CAD); generalising the 28–34% MACE reduction to the asymptomatic 40-year-old is not warranted. Annual revaccination over many decades carries unknown long-term immunological consequences (the antigenic original sin / repeated-exposure literature is genuinely unsettled). And the H3N2 effectiveness problem is structural — egg adaptation plus 8-month lead time on strain selection — and won't be solved by recommending more vaccination.

Author's call. The vaccine is a clear net positive for nearly all adults, with effect size scaling sharply with cardiovascular risk and age. For a healthy 30-year-old the case is modest individual benefit + community contribution; for a 70-year-old with prior MI it is one of the highest-yield single annual interventions available. The cardiovascular protection is the most under-appreciated finding — a reader who walks away knowing only this and getting the shot gets disproportionate value. The H3N2 effectiveness gap is real but is not a reason to skip the vaccine; the enhanced ≥65 products and recombinant ≥50 product partially address it. Overall evidence: 4, controversy: 2 — the field is mostly aligned; the genuine disagreement is over magnitude and not direction.

Stakeholder + incentive map

Public health / regulatory: CDC/ACIP, WHO, ECDC, NHS — strongly pro-vaccination, with explicit annual recommendations. Their incentive is population health and outbreak preparedness; their bias is toward broad recommendations that are easy to communicate (everyone ≥6 months).
Cardiology guidelines: AHA/ACC, ESC — now explicitly recommend influenza vaccination as secondary prevention after acute coronary syndrome (Class I, Level B evidence in ESC 2021 ACS guideline).
Manufacturers: Sanofi (Fluzone HD), Seqirus (Fluad, Flucelvax), GSK (Flulaval), AstraZeneca (FluMist), Sanofi/Protein Sciences (Flublok). Commercial incentive to expand age-band recommendations and prefer enhanced products.
Independent academic critics: Tom Jefferson and the Cochrane influenza group, who have argued the public-health establishment overstates seasonal vaccine benefit. Their work is methodologically careful; the disagreement is on magnitude, not on whether the vaccine works.
Anti-vaccine activism: a separate, generally evidence-free strand. Not a serious source of editorial uncertainty, but a real driver of the population-level VE problem (uptake gaps).

Population variability

Age: sharply non-linear. Healthy adults 18–49 have the most robust vaccine response but the lowest absolute risk; ≥65 have weaker response and highest absolute risk, which is why enhanced products exist for that band. Pregnant women have higher influenza complication risk and are a priority group; maternal vaccination also confers protection to the infant for the first ~6 months of life via transplacental antibody.
Cardiovascular status: the population where the vaccine's value most exceeds the average. Post-ACS, established CAD, heart failure: 28–34% MACE reduction Behrouzi et al. 2022.
Chronic respiratory disease: asthma, COPD — disproportionate hospitalisation reduction with vaccination, plus reduced exacerbations.
Immunocompromise: attenuated antibody response, but recommendation still strongly applies; live attenuated nasal spray contraindicated.
Healthcare workers and household contacts of high-risk individuals: primary benefit is interruption of transmission to those who can't mount a response.
BMI/metabolic syndrome: emerging signal of attenuated vaccine response in obesity, possibly mediated by chronic inflammation; not yet load-bearing for product recommendations.

Knowledge gaps

The largest open question is the magnitude of CV protection in the general (non-CAD) population — extrapolating from the IAMI / Behrouzi datasets to asymptomatic middle-aged adults is not strictly supported. A second open question is the long-term consequence of decades of annual revaccination on heterosubtypic immunity and original-antigenic-sin dynamics; the field's epidemiology has been reassuring but not definitive. The H3N2 effectiveness deficit — partially structural (egg adaptation), partially evolutionary (faster drift than the selection cadence handles) — will probably require either a universal influenza vaccine (broadly conserved-epitope strategies) or year-round real-time strain selection (mRNA platforms could deliver this) to close, and both are active research areas. Effect-size in obese adults, in HIV/immunocompromised cohorts, and in the very oldest old (≥85) remain less precisely characterised than the central ≥65 estimate. What would change the call: a large RCT in primary-prevention CV patients showing the MACE reduction generalises (would push longevity up); convincing replication of the repeated-vaccination interference finding (would not change the recommendation but would refine the framing).

Scope of the brief, end to end. The brief named illness risk and severity, hospitalisation, post-infection cardiovascular events, transmission, and protection in older and high-risk adults. All five are covered: illness risk in the dek + payoff, severity in stakes, hospitalisation in mechanism + audience, CV events as the leading hook through dek / stakes / audience / payoff, transmission threaded through misconceptions (community link) and audience (healthcare workers), and the high-risk / older audience case as its own audience block plus the protocol callout. No silent narrowing.

Lead hook is the cardiac story, not the flu week. The intuitive lede would be "you'll be less likely to get the flu." The under-told finding is the post-influenza acute MI window — Kwong's 6× signal plus the IAMI / Behrouzi RCT-level secondary-prevention data. Most readers haven't seen it; cardiology guidelines have already adopted it; the marginal information value to the typical reader is high. The dek leads with it and the tagline carries it.

Dream narrative written below 40. Overall computed at ~35. Written by choice because the entry's payoff is a clean relief lever (the week not lost, the heart attack not triggered, the people not infected) and the cardiac finding deserved sharper voice than the straight register would have given the dek and tagline.

Rating difficulties.

health_short_term at 2 rather than 3 — the absolute benefit in healthy adults is ~1–2 percentage points per season (Cochrane NNV ~71). "Clear functional improvement" reads as overclaim; "real but small" is the honest read.
longevity at 3 — the average healthy adult gets a modest mortality reduction; the over-65 and CAD subgroups get something substantially larger. Landed holistically rather than splitting between populations.
evidence at 4 not 5 — Cochrane reviews and multiple major RCTs would support 5, but the persistent H3N2 effectiveness gap and season-to-season variability hold it back. The vaccine works; the question is by how much in any given winter.
pull at 1 — between 0 (aversive like a colonoscopy) and 2 (neutral). The pharmacy shot is mildly disliked but not dreaded.

Out of scope, intentional: paediatric primary series (different schedule), universal influenza vaccine candidates (research-only), pandemic-strain stockpile vaccines (H5/H7, public health policy not reader action), and antiviral treatment (oseltamivir, baloxavir — a treatment decision, briefly signposted in out-of-scope).

Future-link candidates: pneumococcal vaccines (PCV20, PPSV23), RSV vaccine, shingles vaccine (Shingrix), Tdap, COVID-19 booster, apoB testing, statin therapy, post-MI secondary prevention bundle.

Separate-entry candidate: "Post-influenza cardiovascular risk window" as a standalone know entry — the Kwong 6× MI finding deserves its own page once the catalogue is denser; for now it lives inside this entry.